ClinicalTrials.gg
CompletedNCT07141381Updated May 8, 2026

A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755

A Phase 1 interventional study of VRN110755 and Rabeprazole in Healthy, sponsored by Voronoi, Inc. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Voronoi, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, open-label, randomized, single-center study to evaluate the effect of food and a proton pump inhibitor (PPI) on the pharmacokinetics (PK) of VRN110755 in healthy adult participants. The primary aim of this study is to assess the impact of food and rabeprazole co-administration on the systemic exposure of VRN110755. Safety and tolerability will also be evaluated.

Read the detailed description

The study consists of two treatment sequences in a 3-period, crossover design. Approximately 24 healthy adult participants will be randomized 1:1 to one of the following sequences:

Sequence 1: Participants will receive VRN110755 80 mg orally in the fasted state (Period 1), then in the fed state (Period 2), and finally in the fed state with 5 days of rabeprazole pre-treatment (Period 3).

Sequence 2: Participants will receive VRN110755 80 mg orally in the fed state (Period 1), then in the fasted state (Period 2), and finally in the fasted state with 5 days of rabeprazole pre-treatment (Period 3).

Rabeprazole 20 mg will be administered orally once daily for 5 consecutive days prior to the final dosing of VRN110755 in Period 3.

All participants will remain under clinical observation for safety monitoring and pharmacokinetic sampling throughout each period. Blood and urine samples will be collected at defined intervals for the analysis of VRN110755 and its metabolites.

Each participant's total study duration will be approximately 76 days, including screening, treatment, and follow-up.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Voronoi, Inc is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged between 18 and 65 years, inclusive, at the time of .
  2. In good general health, with no significant medical history and no abnormalities on physical examination, as determined by the investigator.
  3. (BMI) between 18.0 and 32.0 kg/m², and weight ≥ 50 kg at screening.
  4. Clinical laboratory values within normal ranges, unless deemed not clinically significant by the investigator.
  5. Female participants of who are sexually active with a male partner must agree to use highly effective methods from screening through 6 months after the last dose of product.
  6. Female participants must have a negative pregnancy test at screening and pre-dose.
  7. Women not of childbearing potential must be surgically sterile or for ≥12 months.
  8. Male participants must agree to use barrier contraception in conjunction with a highly effective method if engaging with women of childbearing potential, from screening through 6 months after the last dose.
  9. Male participants must not donate sperm, and female participants must not donate ova, from the first dose through 6 months after the last dose.
  10. Able and willing to comply with study procedures and site visits.
  11. Able and willing to provide written informed consent before any study procedures are performed.

Exclusion criteria

Exclusion Criteria:

  1. Any significant medical or psychiatric condition that may interfere with study participation or interpretation of results, as determined by the investigator.
  2. abnormal findings, including > 450 ms (males) or > 470 ms (females).
  3. Abnormal vital signs at screening (e.g., systolic BP > 140 or \< 90 mmHg, diastolic BP > 90 or \< 60 mmHg, or history of symptomatic hypotension).
  4. Active liver disease, or /ALT > 1.5 × .
  5. Known or suspected gastrointestinal disorders that may interfere with drug absorption (e.g., IBD, chronic diarrhea, malabsorption).
  6. Positive urine drug screen or alcohol breath test at screening.
  7. Regular alcohol use >14 standard drinks/week or >3 drinks/day.
  8. Positive test for , (HBsAg), or antibody.
  9. History of severe allergies or anaphylaxis, or known to study drug components.
  10. Recent infections requiring parenteral antibiotics within 6 months before first dose.
  11. Vaccination with within 4 weeks prior to first dose.
  12. Blood donation >400 mL within 60 days, or component donation within 30 days prior to dosing.
  13. ≤ 90 mL/min/1.73 m² at screening.
  14. Use of nicotine-containing products within 7 days before dosing or unwillingness to abstain during the study.
  15. Use of prescription/OTC medications, herbal products, or supplements within 14 days prior to dosing, unless approved by the investigator.
  16. Use of inhibitors/inducers or medications affecting metabolism of VRN110755 within 14 days prior to dosing.
  17. Unwillingness to follow dietary restrictions (e.g., cannot consume high-fat meals).
  18. Use of proton pump inhibitors, H2 blockers, or antacids within 8 weeks prior to first dose (except planned rabeprazole use in study).
  19. Known hypersensitivity to PPIs (e.g., rabeprazole).
  20. Planned or current participation in another trial or use of another investigational product within 30 days or 5 half-lives.
  21. Poor peripheral venous access.
  22. Any condition that, in the opinion of the investigator, would jeopardize participant safety or interfere with study compliance or data integrity.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Sequence 1: Fasted → Fed → Fed with PPI

    Participants in this sequence will receive VRN110755 80 mg orally under the following conditions across three periods: Period 1: Fasted state Period 2: Fed state (standard high-fat meal) Period 3: Fed state after 5 days of rabeprazole 20 mg daily

    Drug: VRN110755

  • Experimental
    Sequence 2: Fed → Fasted → Fasted with PPI

    Participants in this sequence will receive VRN110755 80 mg orally under the following conditions across three periods: Period 1: Fed state (standard high-fat meal) Period 2: Fasted state Period 3: Fasted state after 5 days of rabeprazole 20 mg daily

    Drug: Rabeprazole

Interventions

  • DrugVRN110755

    VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule. It will be given to all participants under fasted, fed, and PPI pre-treated conditions across three periods in a crossover design.

  • DrugRabeprazole

    Rabeprazole 20 mg will be administered orally once daily for 5 days prior to VRN110755 dosing in Period 3. This is to assess the effect of increased gastric pH (via proton pump inhibition) on the pharmacokinetics of VRN110755.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC₀-inf) of VRN110755

    To evaluate the effect of food and rabeprazole on the extent of systemic exposure of VRN110755 by measuring AUC₀-inf under fasted, fed, and PPI conditions.

    Time frame: Up to 312 hours post-dose (for each treatment period)

  2. Maximum Observed Plasma Concentration (Cmax) of VRN110755

    To assess the peak plasma concentration of VRN110755 under different dosing conditions (fasted, fed, fed/fasted + PPI).

    Time frame: Up to 312 hours post-dose (for each treatment period)

  3. Time to Maximum Observed Concentration (Tmax) of VRN110755

    To assess the time to reach peak concentration of VRN110755 after single-dose oral administration under different conditions.

    Time frame: Up to 312 hours post-dose (for each treatment period)

  4. Comparison of Pharmacokinetic Parameters (AUC and Cmax Ratios) Across Treatment Conditions

    To compare AUC and Cmax values of VRN110755 between fed vs. fasted, and PPI vs. non-PPI conditions using statistical analysis.

    Time frame: Up to 312 hours post-dose (for each treatment period)

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    To evaluate the safety and tolerability of single oral doses of VRN110755 administered under fasted, fed, and PPI conditions by assessing the incidence, severity, and relationship of TEAEs.

    Time frame: From Day 1 of Period 1 through the End of Study (approximately 76 days per participant)

  2. Incidence of Serious Adverse Events (SAEs)

    To monitor and document any SAEs occurring after VRN110755 administration under any treatment condition.

    Time frame: From Day 1 of Period 1 through the End of Study (approximately 76 days per participant)

  3. Number of Participants with Abnormal Clinical Laboratory Test Results

    The number of participants exhibiting abnormal laboratory values in hematology, biochemistry, coagulation, or urinalysis assessments..

    Time frame: Baseline (Day 1), pre-dose on Day 15 and Day 34, and End-of-Study Visit (Day 48)

  4. Change in 12-lead ECG Parameters From Baseline

    Change from baseline in ECG parameters, including heart rate, PR interval, QRS duration, QT interval, and QTcF (Fridericia). ECGs will be recorded after at least 5 minutes of rest in the supine position. Triplicate ECGs will be taken at screening; single ECGs will be performed at other scheduled timepoints unless clinically indicated.

    Time frame: Baseline (Day 1), pre-dose on Day 15 and Day 34, and End-of-Study Visit (Day 48)

  5. Change in Systolic Blood Pressure From Baseline

    Change from baseline in systolic blood pressure measured after at least 5 minutes of rest in the supine position. Triplicate readings will be performed at pre-dose; single measurements at other scheduled timepoints.

    Time frame: Baseline (Day 1), pre-dose on Day 15 and Day 34, and End-of-Study Visit (Day 48).

  6. Change in Diastolic Blood Pressure From Baseline

    Change from baseline in diastolic blood pressure measured after at least 5 minutes of rest in the supine position. Triplicate readings will be performed at pre-dose; single measurements at other scheduled timepoints.

    Time frame: Baseline (Day 1), pre-dose on Day 15 and Day 34, and End-of-Study Visit (Day 48).

  7. Change in Pulse Rate From Baseline

    Change from baseline in pulse rate measured after at least 5 minutes of rest in the supine position. Triplicate readings will be performed at pre-dose; single measurements at other scheduled timepoints.

    Time frame: Baseline (Day 1), pre-dose on Day 15 and Day 34, and End-of-Study Visit (Day 48).

  8. Change in Respiratory Rate From Baseline

    Change from baseline in respiratory rate measured after at least 5 minutes of rest in the supine position. Triplicate readings will be performed at pre-dose; single measurements at other scheduled timepoints.

    Time frame: Baseline (Day 1), pre-dose on Day 15 and Day 34, and End-of-Study Visit (Day 48).

  9. Change in Tympanic Temperature From Baseline

    Change from baseline in tympanic temperature measured after at least 5 minutes of rest in the supine position. Triplicate readings will be performed at pre-dose; single measurements at other scheduled timepoints.

    Time frame: Baseline (Day 1), pre-dose on Day 15 and Day 34, and End-of-Study Visit (Day 48).

  10. Cumulative Amount Excreted (Ae) of VRN110755

    Cumulative amount of VRN110755 excreted in urine, measured over 0 to 24 hours post-dose under different study conditions.

    Time frame: 0 to 24 hours post-dose in each study period.

  11. Fraction Excreted (Fe) of VRN110755

    Fraction of the administered dose of VRN110755 excreted in urine, measured over 0 to 24 hours post-dose under different study conditions.

    Time frame: 0 to 24 hours post-dose in each study period.

  12. Renal Clearance (CLr) of VRN110755

    Renal clearance of VRN110755, determined from urinary excretion and plasma concentration data under different study conditions.

    Time frame: 0 to 24 hours post-dose in each study period.

07

Study locations

1 site
  • CMAX Clinical Research Pty Ltd
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Dec 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 26, 2025
StartActual
Aug 27, 2025
Primary completionActual
Dec 17, 2025
CompletionActual
Apr 16, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07141381
Lead sponsor
Voronoi, Inc
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Aug 27, 2025
Primary completion
Dec 17, 2025
Completion
Apr 16, 2026
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion